Gufic Biosciences Peer Comparison

NSE: GUFICBIO | BSE: 509079

₹442.15

₹6.50 (1.49%)

As on 22-Sep-2026IST

Market cap

₹4,433 Cr

Revenue (TTM)

₹981 Cr

P/E Ratio

60.4

P/B Ratio

6.5

Div. Yield

0 %

Edit

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	4,433	21,126	20,208	17,656	18,275
Revenue (₹ Cr)	981	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	73.45	678.07	273.51	666.92	735.15
Net Margin (%)	7.47	28.10	16.19	20.60	26.88
RoE (%)	11.33	19.73	11.15	18.75	19.16
Price to Earnings	60.35	31.75	67.97	27.42	24.86
Price-To-Book	6.45	5.75	7.52	4.38	4.15

Income Statement (₹ Cr)

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	981.10	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	983.29	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	816.46	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	164.64	796.58	478.55	1,139.61	941.63
Depreciation	30.82	78.10	126.01	281.06	57.58
EBIT	133.82	718.48	352.55	858.55	884.05
Interest	36.70	0.88	52.11	190.64	7.69
Other Income	2.19	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	99.31	843.56	319.96	658.12	992.82
Provision for Tax	25.86	165.49	46.45	-8.80	257.67
Profit after Tax	73.45	678.07	273.51	666.92	735.15

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	664.95	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	159.54	28.74	266.35	1,392.75	91.50
Current Liabilities	517.85	385.94	848.06	2,077.10	627.48
Total Liabilities	--	4,037.51	3,705.61	7,246.72	4,921.88

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	497.69	1,291.22	2,525.44	5,617.77	770.28
Current Assets	802.12	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	--	4,037.51	3,705.61	7,246.72	4,921.88
Total Debt*	--	0.57	657.97	2,309.68	2.50
Net Current Assets	284.27	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	--	17.53	160.01	51.57	370.49

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	--	523.24	342.18	537.99	967.57
Cash Flow from Investing Activities	--	-582.30	-325.92	-369.46	-561.67
Cash from Financing Activities	--	-46.46	13.62	-313.53	-798.31
Net Cash Inflow / Outflow	--	-105.52	29.88	-145.00	-392.41

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	--	24.97	11.43	14.47	23.39
ROE (%)	11.33	19.73	11.15	18.75	19.16
ROA (%)	5.85	18.69	7.80	9.26	14.95
EBIT Margin (%)	13.64	31.41	20.95	26.58	34.40
Net Margin (%)	7.47	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	16.70	15.01	27.91	9.59	10.69
EBIT Growth (%)	24.21	18.45	58.32	16.84	24.14
Net Profit Growth (%)	18.73	19.61	149.56	62.68	-9.09
EPS Growth (%)	18.72	17.73	-3.57	67.41	14.40
Book Value Growth (%)	--	26.75	9.67	36.71	-0.34

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	60.36	31.75	72.10	26.76	23.69
Price / Book Value	6.45	5.75	7.52	4.38	4.15
Dividend Yield (%)	0.02	0.29	0.06	0.00	1.88
EV/EBITDA	28.81	25.26	43.51	17.46	16.11
Market Cap (₹ Cr)	--	11,439.22	6,819.66	17,980.08	21,592.90

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.16	0.00	0.07	0.24	0.00
Short term debt to equity ratio	--	0.00	0.16	0.12	0.00
Current Ratio	1.55	6.70	1.31	0.74	6.06
Quick Ratio	0.92	5.59	0.88	0.53	5.31
Interest Coverage	3.71	959.59	7.14	4.45	130.11

	Gufic Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	30.31	36.10	30.84	21.07	7.07
Asset Turnover	0.78	0.63	0.48	0.45	0.52
Receivable days	--	121.68	113.81	63.88	26.06
Inventory Days	--	63.83	84.76	43.27	65.95
Payable days	--	108.28	101.94	151.85	81.01
Cash Conversion Cycle	--	77.23	96.62	-44.70	11.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.